Capricorn Fund Managers Ltd Invests $17.57 Million in Structure Therapeutics Inc. Sponsored ADR $GPCR

Capricorn Fund Managers Ltd bought a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 252,600 shares of the company’s stock, valued at approximately $17,568,000. Structure Therapeutics makes up about 4.2% of Capricorn Fund Managers Ltd’s investment portfolio, making the stock its 3rd largest holding. Capricorn Fund Managers Ltd owned approximately 0.42% of Structure Therapeutics as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. E. Ohman J or Asset Management AB bought a new stake in Structure Therapeutics during the 4th quarter valued at approximately $314,000. Gilbert & Cook Inc. bought a new position in shares of Structure Therapeutics in the 4th quarter worth approximately $395,000. JPMorgan Chase & Co. raised its position in shares of Structure Therapeutics by 37.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 58,148 shares of the company’s stock worth $1,628,000 after acquiring an additional 15,706 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in shares of Structure Therapeutics in the 3rd quarter valued at approximately $6,856,000. Finally, Paradigm Biocapital Advisors LP bought a new stake in shares of Structure Therapeutics during the third quarter valued at approximately $10,440,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Stock Performance

Shares of GPCR stock opened at $53.48 on Monday. The company has a market capitalization of $3.79 billion, a price-to-earnings ratio of -67.70 and a beta of -1.17. Structure Therapeutics Inc. Sponsored ADR has a one year low of $13.22 and a one year high of $94.90. The company’s 50-day moving average is $64.67 and its 200 day moving average is $52.83.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.14). As a group, research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on GPCR. JPMorgan Chase & Co. upped their price target on Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, January 22nd. Guggenheim boosted their target price on shares of Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. The Goldman Sachs Group raised shares of Structure Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Thursday, January 22nd. Finally, Jefferies Financial Group set a $125.00 price target on shares of Structure Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Structure Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $110.00.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.